According to background information in the article, pancreatic transplantation is a therapeutic option for patients with complicated diabetes mellitus. The American Diabetes Association supports the procedure for patients with diabetes who have had, or need, a kidney transplant. In the absence of kidney failure, pancreas transplantation may be considered for patients with diabetes and severe and frequent metabolic instability, i.e., episodes of very low blood glucose levels (hypoglycemia) or high blood glucose levels with buildup of blood acids (ketoacidosis).
According to the article, solitary pancreas transplantation (i.e., pancreas alone or pancreas-after-kidney) for diabetes mellitus remains controversial due to procedure-associated illness and/or death, toxicity of immunosuppression, expense, and unproven effects on the secondary complications of diabetes. Whether transplantation offers a survival advantage over conventional therapies for diabetes is unknown.
Jeffrey M. Venstrom, B.S., of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., and colleagues compared the survival of pancreas transplant recipients in patients with diabetes and preserved kidney function with that of similar patients listed for a pancreas transplant, since they would have conditions similar to those who underwent the transplant procedure.
The study was conducted using data from 124 transplant centers in the United States, with 11,572 patients with diabetes mellitus on the waiting list for pancreas transplantation (pancreas alone, pancreas-after-kidney, or simultaneous pancreas-kidney) at the United Network for Organ Sharing/Organ Procurement and Transplantation Network between January 1, 1995, and December 31, 2000.
The researchers found that over four years of follow-up, the transplant recipients, compared with patients awaiting the same procedure, had a 57 percent increased risk of death for pancreas transplant alone; 42 percent increased risk of death for pancreas-after-kidney transplant patients; and 57 percent decreased risk of death for simultaneous pancreas-kidney transplant "Transplant patient 1- and 4-year survival rates were 96.5 percent and 85.2 percent for pancreas transplant alone, respectively, and 95.3 percent and 84.5 percent for pancreas-after-kidney transplant, while 1- and 4-year survival rates for patients on the waiting list were 97.6 percent and 92.1 percent for pancreas transplant alone, respectively, and 97.1 percent and 88.1 percent for pancreas-after-kidney transplant," the authors write.
"Our data suggest that patients with complicated diabetes who are considering a solitary pancreas transplant must weigh the potential benefit of insulin independence against an apparent increase in mortality for at least the first 4 years posttransplantation. Benefits not accounted for in this analysis (e.g., improved quality of life) may justify pancreas transplantation, and it is possible that transplant recipients may show a survival advantage with longer-term follow-up. Even if that is true, however, it is at best difficult to weigh the cost of an early excess mortality (spanning the first 4 years posttransplant) against what at this point is a hypothetical survival advantage beyond the 4 years we have analyzed," the researchers write.
"At this point, clinicians and patients considering the pancreas transplant option must understand the actual risks and benefits, the expense, and the uncertainties associated with this surgical therapy. Our data suggest that the increasingly frequent application of the solitary pancreas transplantation option for those with normal kidney function warrants a second look," they conclude.
(JAMA. 2003;290:2817-2823. Available post-embargo at JAMA.com)
Editor's Note: This work was supported in part by intramural funds of the National Institute of Diabetes & Digestive and Kidney Diseases/National Institutes of Health/Department of Health and Human Services and Health Resources and Services Administration.
COMMENTARY: ISOLATED PANCREAS TRANSPLANTATION FOR TYPE 1 DIABETES
In an accompanying commentary, David M. Nathan, M.D., of Massachusetts General Hospital, and Harvard Medical School, Boston, writes that the Venstrom et al study has several important implications.
"First, the absence of controlled clinical trials represents a major barrier to understanding and balancing the risks and benefits of these procedures. Second, the increased early mortality in the postoperative period, without an apparent longer-term survival benefit, should temper enthusiasm for pancreas transplant alone and pancreas-after-kidney transplantation. There may be some patients in whom quality of life is so severely compromised that the potential benefits of pancreas transplant alone and pancreas-after-kidney transplantation outweigh the risks. However, such patients must be selected very carefully and be fully informed of the results of the current study."
"Moreover, the severe limitation of donor pancreata means that pancreas transplant alone and pancreas-after-kidney transplantation decreases the available organs for simultaneous pancreas-kidney procedures, which are more justifiable. Finally, at least part of the explanation for the differences in outcome between the recipients of pancreas transplant alone and pancreas-after-kidney transplant and the corresponding patients on the waiting list is that improvements in routine care of diabetes have improved the long-term outlook for all diabetic patients," Dr. Nathan concludes.
(JAMA. 2003;290:2861-2863. Available post-embargo at JAMA.com)
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.